Combination of Serum Biomarkers to Differentiate Malignant From Benign Ovarian Tumours

@article{He2012CombinationOS,
  title={Combination of Serum Biomarkers to Differentiate Malignant From Benign Ovarian Tumours},
  author={Gang He and Christina A. Holcroft and M S Beauchamp and Amber Yasmeen and Alex S Ferenczy and Jennifer Kendall-Dupont and Anne-Marie Mes-Masson and Diane Mich{\`e}le Provencher and Walter Henri Gotlieb},
  journal={Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC},
  year={2012},
  volume={34 6},
  pages={
          567-574
        }
}
OBJECTIVE To investigate biomarkers and clinical parameters to distinguish ovarian cancers from benign ovarian tumours. METHODS Serum biomarkers (CA 125, human epididymis protein 4 [HE 4], interleukin-18 [IL-18], leptin, macrophage migration inhibitory factor [MIF], fibroblast growth factor 2 [FGF-2], insulin-like growth factor, osteopontin, prolactin) and the risk of malignancy indexes I and II (RMI-I and RMI-II) scores were obtained prior to surgery in 52 patients with ovarian tumours (37… CONTINUE READING

From This Paper

Topics from this paper.